Lantern Pharma Unveils New Features for withZeta.ai Platform
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy LTRN?
Source: Newsfilter
- Feature Launch: Lantern Pharma has introduced new capabilities for the withZeta.ai platform, including ZetaSwarm™ and ZetaOmics™, aimed at enhancing efficiency in oncology research and drug development, which is expected to attract more biomedical research institutions.
- Significant Market Potential: With the AI-driven drug development market projected to reach $15 billion, the commercial subscription model of withZeta.ai provides Lantern Pharma shareholders with a new non-dilutive revenue stream, enhancing the company's financial stability.
- Multi-Agent Intelligence System: ZetaSwarm™ is designed to process scientific sub-problems in parallel using 34 tools and real data, providing more precise support for drug development, which is anticipated to significantly improve R&D efficiency and outcome quality.
- Enterprise-Grade Platform Capabilities: The newly developed enterprise features will support research deployments for pharmaceutical companies and academic institutions, offering role-based access controls and comprehensive audit trails to ensure compliance and enhance user experience.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LTRN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LTRN
Wall Street analysts forecast LTRN stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.040
Low
25.00
Averages
25.00
High
25.00
Current: 2.040
Low
25.00
Averages
25.00
High
25.00
No data
About LTRN
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lantern Pharma Unveils New Features for withZeta.ai Platform
- Platform Upgrade: Lantern Pharma's withZeta.ai platform will integrate ZetaSwarm™ and ZetaOmics™ capabilities, aiming to enhance efficiency in oncology research and drug development through real-time multi-omic computational analyses and multi-agent reasoning, thereby securing a competitive edge in the nearly $15 billion AI drug development market.
- New Revenue Stream: withZeta.ai is now commercially available with a fully enabled subscription payment model serving the biomedical research and drug development community, expected to provide Lantern Pharma shareholders with a new non-dilutive revenue stream, further enhancing the company's financial stability.
- Enterprise Features Development: The platform is developing enterprise-grade capabilities to support research deployments at pharmaceutical companies and academic medical centers, with planned features including workspace and organization-level accounts, comprehensive audit trails, and private knowledge bases to meet compliance requirements and enhance user experience.
- Agent Collaboration Innovation: ZetaSwarm™ will utilize a coordinated network of specialist AI agents to tackle complex scientific questions, leveraging 34 tools and real data for in-depth analysis, which is expected to significantly shorten research cycles and improve the speed and accuracy of drug development.
See More
Lantern Pharma Unveils New Features for withZeta.ai Platform
- Feature Launch: Lantern Pharma has introduced new capabilities for the withZeta.ai platform, including ZetaSwarm™ and ZetaOmics™, aimed at enhancing efficiency in oncology research and drug development, which is expected to attract more biomedical research institutions.
- Significant Market Potential: With the AI-driven drug development market projected to reach $15 billion, the commercial subscription model of withZeta.ai provides Lantern Pharma shareholders with a new non-dilutive revenue stream, enhancing the company's financial stability.
- Multi-Agent Intelligence System: ZetaSwarm™ is designed to process scientific sub-problems in parallel using 34 tools and real data, providing more precise support for drug development, which is anticipated to significantly improve R&D efficiency and outcome quality.
- Enterprise-Grade Platform Capabilities: The newly developed enterprise features will support research deployments for pharmaceutical companies and academic institutions, offering role-based access controls and comprehensive audit trails to ensure compliance and enhance user experience.
See More
Highlights from New to The Street Broadcast
- Rich Program Content: Tonight's episode #746 of New to The Street will air on Bloomberg Television, reaching millions of households across the U.S., MENA, and Latin America, showcasing innovations and developments from various companies.
- Industry Leaders Speak: Dr. Jonathan C. Javitt, CEO of NRx Pharmaceuticals, discusses the company's innovative pipeline in critical care and neuropsychiatric treatments, emphasizing its leading position in the healthcare sector.
- Digital Transformation: Performance Golf, a leading digital golf instruction platform, is transforming how players improve their game worldwide, demonstrating the potential of technology in traditional sports.
- Diverse Sponsorships: The program is further supported by commercial sponsorships from Medicus Pharma, IGC Pharma, Roadzen, and Lantern Pharma, enhancing its influence in the healthcare, AI, and technology sectors.
See More
Lantern Pharma Launches AI Drug Discovery Platform with Subscription Tiers
- Platform Launch: Lantern Pharma announced the commercial launch of its AI-driven drug discovery platform, withZeta.ai, offering introductory, academic, and commercial subscription tiers, creating a new non-dilutive revenue stream for shareholders.
- Nasdaq Market Showcase: On April 16, 2026, Lantern will host an exclusive live demonstration at Nasdaq MarketSite, attracting 25 leading biotech investors and analysts to showcase the platform's real-time multi-database querying and molecule development capabilities, marking a significant milestone in presenting its commercial progress to institutional investors.
- AACR 2026 Debut: Lantern will showcase withZeta.ai at the American Association for Cancer Research Annual Meeting from April 17-22, 2026, attracting global cancer researchers and biopharma executives, demonstrating its application potential in rare cancer drug development, which is expected to expand its commercial subscriber base.
- Market Opportunity: The global AI drug discovery market is projected to exceed $15 billion by 2030, with withZeta.ai positioned as a fully deployed subscription platform aimed at transforming the economics of rare cancer drug development by compressing the costs and time of research and hypothesis generation phases.
See More
Lantern Pharma Unveils AI Drug Development Platform with Zeta.ai
- Investor Briefing: Lantern Pharma will host an investor, analyst, and shareholder briefing on April 9, 2026, showcasing its collaboration with Zeta.ai on a multi-agentic AI platform aimed at addressing critical challenges in rare cancer drug development, which is expected to attract significant attention and boost market confidence.
- Market Opportunity: The global AI drug discovery market is projected to exceed $15 billion by 2030, with rare cancers identified as the most underserved and urgent opportunity, positioning Lantern Pharma's platform to capture a meaningful share through a scalable subscription model, driving future growth.
- Technological Advantage: The multi-agentic architecture of withZeta.ai enables research workflows to simultaneously query multiple knowledge bases, significantly enhancing research efficiency, which is expected to shorten drug development timelines, reduce costs, and accelerate clinical trial processes.
- Business Model: Lantern Pharma will detail its commercial subscription model during the briefing, covering a broad customer base from individual researchers to global pharmaceutical companies, which is anticipated to generate substantial revenue growth and strengthen its position in a competitive market.
See More
Lantern Pharma Q4 2025 Earnings Call Insights
- Significant Clinical Progress: Lantern Pharma achieved clinical validation across multiple programs in 2025, particularly with LP-300 in the Phase II HARMONIC trial, which demonstrated an 86% clinical benefit rate and a 43% objective response rate, indicating potential breakthroughs in cancer treatment.
- Urgent Funding Needs: Management emphasized the necessity to raise substantial additional funding in the near future to support clinical program advancements, with current cash expected to last until late July or mid-September 2026, highlighting operational pressures.
- AI Innovation Commercialization: The company launched the withZeta multi-agentic system aimed at conquering rare cancers and established an AI center of excellence in India, reflecting Lantern Pharma's strategic focus on AI-driven clinical pipelines and commercialization.
- Improved Financial Performance: In Q4 2025, R&D expenses were $2.7 million, significantly down from $4.3 million in the prior year, with a net loss of $4.1 million, demonstrating the company's efforts in cost control and gradual improvement in financial health.
See More
Lantern Pharma Unveils New Features for withZeta.ai Platform
- Platform Upgrade: Lantern Pharma's withZeta.ai platform will integrate ZetaSwarm™ and ZetaOmics™ capabilities, aiming to enhance efficiency in oncology research and drug development through real-time multi-omic computational analyses and multi-agent reasoning, thereby securing a competitive edge in the nearly $15 billion AI drug development market.
- New Revenue Stream: withZeta.ai is now commercially available with a fully enabled subscription payment model serving the biomedical research and drug development community, expected to provide Lantern Pharma shareholders with a new non-dilutive revenue stream, further enhancing the company's financial stability.
- Enterprise Features Development: The platform is developing enterprise-grade capabilities to support research deployments at pharmaceutical companies and academic medical centers, with planned features including workspace and organization-level accounts, comprehensive audit trails, and private knowledge bases to meet compliance requirements and enhance user experience.
- Agent Collaboration Innovation: ZetaSwarm™ will utilize a coordinated network of specialist AI agents to tackle complex scientific questions, leveraging 34 tools and real data for in-depth analysis, which is expected to significantly shorten research cycles and improve the speed and accuracy of drug development.
See More
Lantern Pharma Unveils New Features for withZeta.ai Platform
- Feature Launch: Lantern Pharma has introduced new capabilities for the withZeta.ai platform, including ZetaSwarm™ and ZetaOmics™, aimed at enhancing efficiency in oncology research and drug development, which is expected to attract more biomedical research institutions.
- Significant Market Potential: With the AI-driven drug development market projected to reach $15 billion, the commercial subscription model of withZeta.ai provides Lantern Pharma shareholders with a new non-dilutive revenue stream, enhancing the company's financial stability.
- Multi-Agent Intelligence System: ZetaSwarm™ is designed to process scientific sub-problems in parallel using 34 tools and real data, providing more precise support for drug development, which is anticipated to significantly improve R&D efficiency and outcome quality.
- Enterprise-Grade Platform Capabilities: The newly developed enterprise features will support research deployments for pharmaceutical companies and academic institutions, offering role-based access controls and comprehensive audit trails to ensure compliance and enhance user experience.
See More
Highlights from New to The Street Broadcast
- Rich Program Content: Tonight's episode #746 of New to The Street will air on Bloomberg Television, reaching millions of households across the U.S., MENA, and Latin America, showcasing innovations and developments from various companies.
- Industry Leaders Speak: Dr. Jonathan C. Javitt, CEO of NRx Pharmaceuticals, discusses the company's innovative pipeline in critical care and neuropsychiatric treatments, emphasizing its leading position in the healthcare sector.
- Digital Transformation: Performance Golf, a leading digital golf instruction platform, is transforming how players improve their game worldwide, demonstrating the potential of technology in traditional sports.
- Diverse Sponsorships: The program is further supported by commercial sponsorships from Medicus Pharma, IGC Pharma, Roadzen, and Lantern Pharma, enhancing its influence in the healthcare, AI, and technology sectors.
See More
Lantern Pharma Launches AI Drug Discovery Platform with Subscription Tiers
- Platform Launch: Lantern Pharma announced the commercial launch of its AI-driven drug discovery platform, withZeta.ai, offering introductory, academic, and commercial subscription tiers, creating a new non-dilutive revenue stream for shareholders.
- Nasdaq Market Showcase: On April 16, 2026, Lantern will host an exclusive live demonstration at Nasdaq MarketSite, attracting 25 leading biotech investors and analysts to showcase the platform's real-time multi-database querying and molecule development capabilities, marking a significant milestone in presenting its commercial progress to institutional investors.
- AACR 2026 Debut: Lantern will showcase withZeta.ai at the American Association for Cancer Research Annual Meeting from April 17-22, 2026, attracting global cancer researchers and biopharma executives, demonstrating its application potential in rare cancer drug development, which is expected to expand its commercial subscriber base.
- Market Opportunity: The global AI drug discovery market is projected to exceed $15 billion by 2030, with withZeta.ai positioned as a fully deployed subscription platform aimed at transforming the economics of rare cancer drug development by compressing the costs and time of research and hypothesis generation phases.
See More
Lantern Pharma Unveils AI Drug Development Platform with Zeta.ai
- Investor Briefing: Lantern Pharma will host an investor, analyst, and shareholder briefing on April 9, 2026, showcasing its collaboration with Zeta.ai on a multi-agentic AI platform aimed at addressing critical challenges in rare cancer drug development, which is expected to attract significant attention and boost market confidence.
- Market Opportunity: The global AI drug discovery market is projected to exceed $15 billion by 2030, with rare cancers identified as the most underserved and urgent opportunity, positioning Lantern Pharma's platform to capture a meaningful share through a scalable subscription model, driving future growth.
- Technological Advantage: The multi-agentic architecture of withZeta.ai enables research workflows to simultaneously query multiple knowledge bases, significantly enhancing research efficiency, which is expected to shorten drug development timelines, reduce costs, and accelerate clinical trial processes.
- Business Model: Lantern Pharma will detail its commercial subscription model during the briefing, covering a broad customer base from individual researchers to global pharmaceutical companies, which is anticipated to generate substantial revenue growth and strengthen its position in a competitive market.
See More
Lantern Pharma Q4 2025 Earnings Call Insights
- Significant Clinical Progress: Lantern Pharma achieved clinical validation across multiple programs in 2025, particularly with LP-300 in the Phase II HARMONIC trial, which demonstrated an 86% clinical benefit rate and a 43% objective response rate, indicating potential breakthroughs in cancer treatment.
- Urgent Funding Needs: Management emphasized the necessity to raise substantial additional funding in the near future to support clinical program advancements, with current cash expected to last until late July or mid-September 2026, highlighting operational pressures.
- AI Innovation Commercialization: The company launched the withZeta multi-agentic system aimed at conquering rare cancers and established an AI center of excellence in India, reflecting Lantern Pharma's strategic focus on AI-driven clinical pipelines and commercialization.
- Improved Financial Performance: In Q4 2025, R&D expenses were $2.7 million, significantly down from $4.3 million in the prior year, with a net loss of $4.1 million, demonstrating the company's efforts in cost control and gradual improvement in financial health.
See More
